In a groundbreaking development for global health, the World Health Organization (WHO) has endorsed Lenacapavir, a revolutionary HIV prevention drug, marking a significant step toward combating the HIV/AIDS epidemic. This long-acting injectable, administered twice annually, offers six months of protection against HIV infection and has shown remarkable efficacy in clinical trials.